Mirada Solutions Announces Licensing and Development Agreement with UCLA for KIS -- 'Kinetic Information Systems' Software
24 Junio 2004 - 12:30PM
PR Newswire (US)
Mirada Solutions Announces Licensing and Development Agreement with
UCLA for KIS -- 'Kinetic Information Systems' Software OXFORD,
England, June 24 /PRNewswire-FirstCall/ -- Mirada Solutions Ltd. (a
subsidiary of CTI Molecular Imaging, Inc.), leaders in software for
molecular imaging, have announced today a licensing and development
agreement with the Department of Medical and Molecular
Pharmacology, University of California Los Angeles, for "KIS"
(Kinetic Information Systems). KIS is a novel software environment
which has been designed by Dr. Henry Huang and his colleagues at
UCLA, for the display, analysis and simulation of pharmacokinetic
and biodistribution information with PET. The software reflects
many years of research and experimentation with PET, particularly
for animal imaging. It will be further developed and positioned as
both a freely accessible public domain analysis and educational
tool for the academic community, as well as a commercial extension
to Mirada's product offerings. Christian P. Behrenbruch Ph.D.,
President of Mirada Solutions, commented, "Dr. Huang's team has
built an educational and research tool that we think has immediate
applicability as part of PETNET's education program, as well as a
more long-term potential. The KIS software will be developed
further to become a significant component of CTI's platform for
molecular imaging R&D -- primarily targeted at drug discovery
and clinical trials. KIS is part of the story for 'life after FDG'
as we move towards true molecular imaging applications." Dr Henry
Huang said, "We are pleased to be working with Mirada and CTI to
commercialize and further evolve KIS. KIS captures a lot of the
strength of our group's capabilities in PET and molecular imaging.
It is important that KIS will be developed not only as a generally
accessible research tool that will widely benefit the academic
community, but also as a technology base that is very synergistic
with Mirada's own scientific developments in PET software." About
Mirada Solutions: Mirada Solutions Limited, a wholly owned
subsidiary of CTI Molecular Imaging, is a leading developer of
software and analytical tools for medical imaging workstations, OEM
imaging platforms and pharmaceutical applications. Mirada's unique
products aid in better detection, diagnosis and management of
disease through the application of powerful algorithms,
quantification tools and image analysis. Additional information is
available at http://www.mirada-solutions.com/ . About CTI Molecular
Imaging: CTI Molecular Imaging, Inc. is a leading supplier of
products and services for positron emission tomography (PET), a
diagnostic imaging technology used in the detection and treatment
of cancer, cardiac disease and neurological disorders. Additional
information is available at: http://www.ctimi.com/ . Certain
matters discussed in this press release constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements may be
identified by words such as "believe," "assume," "expect,"
"anticipate," "intend," "estimate" or similar expressions, and any
other statements that necessarily depend on future events.
Forward-looking statements involve a number of risks and
uncertainties and there can be no assurance that any
forward-looking statements will prove to be accurate. Various
factors could cause actual results to differ materially from those
anticipated in the forward-looking statements. CTI undertakes no
obligation to update or revise any forward- looking statements.
Further information regarding risks, uncertainties and other
factors that could adversely affect CTI or cause actual results to
differ materially from those anticipated in forward-looking
statements are included in CTI's Annual Report on Form 10-K for the
fiscal year ended September 30, 2003, Quarterly Report on Form 10-Q
for the quarter ended March 31, 2004. DATASOURCE: CTI Molecular
Imaging, Inc.; Mirada Solutions Ltd. CONTACT: Clare F. Jones of
Mirada Solutions Ltd., +1-44-1865-265-500; or Michael A. Lawless of
CTI Molecular Imaging, Inc., +1-865-218-2000 Web site:
http://www.ctimi.com/ http://www.mirada-solutions.com/
Copyright